Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib in advanced liposarcoma
NCT02978859Phase 2Completed
- Sponsor
- Columbia University
- Start
- Nov 2016
- Primary completion
- Jan 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sitravatinib in Liposarcoma, sponsored by Columbia University. Primary endpoint: Progression-Free Rate at 12 weeks. Started Nov 2016; status: completed.
02
Drugs
sitravatinib
03
Conditions
Liposarcoma
Beyond the preview
Go deeper on NCT02978859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978859.